When we compared the metabolic processes between BPH patients and PCa-T2 stage, BPH showed an increase in NADP and pigment metabolisms through transketolase (TKT) and hemopexin, respectively, while patients with PCa-T2 stage had an exacerbated secondary metabolic process through the aldo-keto reductase family 1 member C3 (AKR1C3). The gene discussed is HPX; the disease is benign prostatic hyperplasia.